BTIG analyst Ryan Zimmerman lowered the firm’s price target on Alcon (ALC) to $87 from $92 and keeps a Buy rating on the shares as part of a broader research note on Medical Technology names. The firm is updating its models given its takeaways after it hosted a booth tour at the American Society of Cataract & Refractive Surgery conference in Washington DC.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- William Blair med tech analyst holds an analyst/industry conference call
- Alcon launches Clareon TruPlus at ASCRS 2026
- Alcon Sets April 30, 2026 AGM, Proposes New Director and CHF 0.28 Dividend
- Sight Sciences awarded monetary damages by district court against Alcon
- Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates